Q32 Bio (QTTB) director granted 53,521 options at $2.8
Q32 Bio (QTTB) reported a Form 4 for a director reflecting a grant of stock options.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Q32 Bio (QTTB) reported a Form 4 for a director reflecting a grant of stock options. The filing lists a Stock Option (Right to Buy) for 53,521 shares at an exercise price of $2.8 per share on 10/23/2025.
These options vest in full upon the earlier of October 23, 2026 or the date of the issuer’s next annual meeting of stockholders, subject to the reporting person’s continued service on the vesting date. The option carries an expiration date of 10/22/2035 and is held directly. The grant price for the derivative security is shown as $0.00, consistent with option awards.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 53,521 | $0.00 | $0.00 |
Footnotes (1)
- F1. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) October 23, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Q32 Bio (QTTB) disclose on this Form 4?
What is the exercise price of the QTTB option grant?
When do the QTTB options vest?
How many options were granted in this QTTB filing?
When do the QTTB options expire?
How is ownership of the options held?
AI-generated analysis. How Rhea-AI works. Not financial advice.